Positive
●
CNBC
●
about one month ago
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes, either as independent treatments or layered on top of existing drugs. A new slate of injections, pills, and combination regimens target the amylin pathway, which involves a hormone released in the pancreas alongside insulin that helps regulate hunger and fullness.